Quest Diagnostics Inc
DGX178.530USD
+1.849+1.05%
Close 04/29, 16:00（ET）Quotes delayed by 15 min
20.00BMarket Cap
23.09P/E TTM
More Details of Quest Diagnostics Inc Company
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company provides diagnostic insights from the results of its laboratory testing to enable people, physicians, and organizations to take action to improve health outcomes. It operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It offers broad access to clinical testing through a nationwide network of laboratories, patient service centers, phlebotomists in physician offices, and connectivity resources, including call centers and mobile phlebotomists, nurses and other health and wellness professionals. It also focuses on artificial intelligence (AI) and digital pathology solutions. The Company’s services primarily are provided under the Quest Diagnostics brand and under other brands, including AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum.
Company Info
Company codeDGX
Company nameQuest Diagnostics Inc
IPO dateDec 17, 1996
Founded at1996
CEOMr. James E. (Jim) Davis
Number of employees45000
Security typeOrdinary Share
Fiscal year-endDec 17
Address500 Plaza Drive
CitySECAUCUS
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code07094
Phone19735202700
Websitehttps://www.questdiagnostics.com/
Company codeDGX
IPO dateDec 17, 1996
Founded at1996
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Catherine T. (Cathy) Doherty
Ms. Catherine T. (Cathy) Doherty
Executive Vice President - Regional Businesses
Executive Vice President - Regional Businesses
72.49K
-1.40%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Lead Independent Director
Lead Independent Director
44.41K
+4.88%
Mr. Michael E. Prevoznik
Mr. Michael E. Prevoznik
Senior Vice President, General Counsel
Senior Vice President, General Counsel
39.12K
-12.25%
Mr. Gary M. Pfeiffer
Mr. Gary M. Pfeiffer
Independent Director
Independent Director
33.68K
+2.00%
Mr. Timothy L. (Tim) Main
Mr. Timothy L. (Tim) Main
Independent Director
Independent Director
25.09K
--
Ms. Vicky B. Gregg
Ms. Vicky B. Gregg
Independent Director
Independent Director
16.87K
--
Mr. Karthik Kuppusamy
Mr. Karthik Kuppusamy
Senior Vice President - Clinical Solutions
Senior Vice President - Clinical Solutions
12.52K
-16.95%
Ms. Denise M. Morrison
Ms. Denise M. Morrison
Independent Director
Independent Director
10.65K
+0.69%
Ms. Tracey C. Doi
Ms. Tracey C. Doi
Independent Director
Independent Director
5.26K
+1.92%
Mr. Robert B. (Rob) Carter
Mr. Robert B. (Rob) Carter
Independent Director
Independent Director
1.48K
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Catherine T. (Cathy) Doherty
Ms. Catherine T. (Cathy) Doherty
Executive Vice President - Regional Businesses
Executive Vice President - Regional Businesses
72.49K
-1.40%
Mr. Timothy M. (Tim) Ring
Mr. Timothy M. (Tim) Ring
Lead Independent Director
Lead Independent Director
44.41K
+4.88%
Mr. Michael E. Prevoznik
Mr. Michael E. Prevoznik
Senior Vice President, General Counsel
Senior Vice President, General Counsel
39.12K
-12.25%
Mr. Gary M. Pfeiffer
Mr. Gary M. Pfeiffer
Independent Director
Independent Director
33.68K
+2.00%
Mr. Timothy L. (Tim) Main
Mr. Timothy L. (Tim) Main
Independent Director
Independent Director
25.09K
--
Ms. Vicky B. Gregg
Ms. Vicky B. Gregg
Independent Director
Independent Director
16.87K
--
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Routine clinical testing services
5.03B
51.00%
Gene-based and esoteric testing services
3.85B
39.00%
Anatomic pathology testing services
592.32M
6.00%
All other
296.16M
3.00%
COVID-19 testing services
98.72M
1.00%
By RegionUSD
Name
Revenue
Proportion
United States
9.87B
100.00%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Routine clinical testing services
5.03B
51.00%
Gene-based and esoteric testing services
3.85B
39.00%
Anatomic pathology testing services
592.32M
6.00%
All other
296.16M
3.00%
COVID-19 testing services
98.72M
1.00%
Shareholder
Update time: Fri, Feb 21
Update time: Fri, Feb 21
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
12.46%
BlackRock Institutional Trust Company, N.A.
5.72%
T. Rowe Price Associates, Inc.
4.77%
State Street Global Advisors (US)
4.68%
Victory Capital Management Inc.
3.01%
Other
69.36%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
12.46%
BlackRock Institutional Trust Company, N.A.
5.72%
T. Rowe Price Associates, Inc.
4.77%
State Street Global Advisors (US)
4.68%
Victory Capital Management Inc.
3.01%
Other
69.36%
Type
Shareholder
Proportion
Investment Advisor/Hedge Fund
43.26%
Investment Advisor
39.46%
Research Firm
3.59%
Hedge Fund
2.38%
Pension Fund
2.23%
Bank and Trust
1.51%
Sovereign Wealth Fund
1.20%
Individual Investor
0.44%
Insurance Company
0.10%
Other
5.83%
Institutional Shareholding
Update time: Mon, Jan 20
Update time: Mon, Jan 20
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
1728
104.89M
94.51%
-2.04M
2024Q4
1799
104.71M
94.35%
-2.70M
2024Q3
1750
102.92M
92.46%
-3.55M
2024Q2
1759
102.88M
92.68%
-4.95M
2024Q1
1761
104.07M
93.75%
-1.69M
2023Q4
1784
101.50M
91.43%
-7.03M
2023Q3
1779
103.39M
92.29%
-7.25M
2023Q2
1792
104.49M
93.26%
-6.44M
2023Q1
1797
105.56M
94.19%
-4.32M
2022Q4
1821
104.62M
94.12%
-9.73M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
13.91M
12.54%
-8.04K
-0.06%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
6.38M
5.75%
-47.02K
-0.73%
Dec 31, 2024
T. Rowe Price Associates, Inc.
5.33M
4.8%
+1.63M
+44.23%
Dec 31, 2024
State Street Global Advisors (US)
5.22M
4.71%
-41.76K
-0.79%
Dec 31, 2024
Victory Capital Management Inc.
3.36M
3.03%
-104.37K
-3.01%
Dec 31, 2024
Geode Capital Management, L.L.C.
2.69M
2.42%
+73.37K
+2.80%
Dec 31, 2024
Davis Selected Advisers, L.P.
2.40M
2.16%
-1.84K
-0.08%
Dec 31, 2024
Grantham Mayo Van Otterloo & Co LLC
2.27M
2.04%
+26.21K
+1.17%
Dec 31, 2024
JP Morgan Asset Management
2.12M
1.91%
+986.50K
+87.23%
Dec 31, 2024
Dimensional Fund Advisors, L.P.
2.04M
1.84%
-5.16K
-0.25%
Dec 31, 2024
View more
Related ETFs
Update time: Sun, Apr 6
Update time: Sun, Apr 6
Name
Proportion
Global X Telemedicine & Digital Health ETF
4.06%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
3.48%
iShares U.S. Healthcare Providers ETF
2.96%
Madison Dividend Value ETF
2.85%
Davis Select US Equity ETF
2.79%
Monarch Volume Factor Dividend Tree Index ETF
2.75%
First Trust Total US Market AlphaDEX ETF
2.29%
Invesco Bloomberg MVP Multi-Factor ETF
2.21%
Invesco Raymond James SB-1 Equity ETF
2.16%
SPDR S&P Health Care Services ETF
2.03%
View more
Global X Telemedicine & Digital Health ETF
Proportion4.06%
AAM Bahl & Gaynor Small/Mid Cap Income Growth ETF
Proportion3.48%
iShares U.S. Healthcare Providers ETF
Proportion2.96%
Madison Dividend Value ETF
Proportion2.85%
Davis Select US Equity ETF
Proportion2.79%
Monarch Volume Factor Dividend Tree Index ETF
Proportion2.75%
First Trust Total US Market AlphaDEX ETF
Proportion2.29%
Invesco Bloomberg MVP Multi-Factor ETF
Proportion2.21%
Invesco Raymond James SB-1 Equity ETF
Proportion2.16%
SPDR S&P Health Care Services ETF
Proportion2.03%
Dividend
A total of
1.56B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Nov 12, 2024
DGX.NB Interim Cash Dividend of gross USD 0.75 paid on Jan 29, 2025 going ex on Jan 14, 2025
Jan 14, 2025
Jan 29, 2025
Jan 14, 2025
Aug 14, 2024
DGX.NB Final Cash Dividend of gross USD 0.75 paid on Oct 21, 2024 going ex on Oct 04, 2024
Oct 04, 2024
Oct 21, 2024
Oct 04, 2024
May 15, 2024
DGX.NB Interim Cash Dividend of gross USD 0.75 paid on Jul 22, 2024 going ex on Jul 08, 2024
Jul 08, 2024
Jul 22, 2024
Jul 08, 2024
Feb 01, 2024
DGX.NB Interim Cash Dividend of gross USD 0.75 paid on Apr 22, 2024 going ex on Apr 05, 2024
Apr 08, 2024
Apr 22, 2024
Apr 05, 2024
Nov 14, 2023
DGX.NB Interim Cash Dividend of gross USD 0.71 paid on Jan 31, 2024 going ex on Jan 16, 2024
Jan 17, 2024
Jan 31, 2024
Jan 16, 2024
Aug 14, 2023
DGX.NB Final Cash Dividend of gross USD 0.71 paid on Oct 23, 2023 going ex on Oct 05, 2023 with reinvestment option
Oct 06, 2023
Oct 23, 2023
Oct 05, 2023
May 16, 2023
DGX.NB Interim Cash Dividend of gross USD 0.71 paid on Jul 25, 2023 going ex on Jul 10, 2023 with reinvestment option
Jul 11, 2023
Jul 25, 2023
Jul 10, 2023
Feb 02, 2023
DGX.NB Interim Cash Dividend of gross USD 0.71 paid on Apr 24, 2023 going ex on Apr 06, 2023 with reinvestment option
Apr 10, 2023
Apr 24, 2023
Apr 06, 2023
Nov 15, 2022
DGX.NB Interim Cash Dividend of gross USD 0.66 paid on Feb 01, 2023 going ex on Jan 17, 2023
Jan 18, 2023
Feb 01, 2023
Jan 17, 2023
Aug 10, 2022
DGX.NB Final Cash Dividend of gross USD 0.66 paid on Oct 19, 2022 going ex on Oct 03, 2022
Oct 04, 2022
Oct 19, 2022
Oct 03, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data